Priavoid’s oral Alzheimer’s drug falters on Phase II efficacy endpoint
While Priavoid’s oral Alzheimer’s disease drug has been shown to be safe and tolerable, it failed to have a significant …
While Priavoid’s oral Alzheimer’s disease drug has been shown to be safe and tolerable, it failed to have a significant …
ONL Therapeutics has concluded patient enrolment in its global Phase II GALAXY clinical trial assessing xelafaslatide for geographic atrophy (GA) …
Sellas Life Sciences’ stock value has soared nearly 150% after its off-the-shelf cancer vaccine, galinpepimut-S (GPS), improved survival outcomes in …
This year marks two decades since the first biosimilar was approved in Europe in 2006. Since then, approximately 165 European …
MSD has discontinued its Phase III BELLWAVE-011 trial assessing nemtabrutinib (MK-1026) for leukaemia and other haematologic malignancies after an external …
Novo’s subcutaneous Wegovy (semaglutide) has reduced body mass index (BMI) by at least 10% in 80% of children with obesity …
AriBio’s once-daily Alzheimer’s pill, AR1001, has demonstrated its potential to slow clinical decline by 31% within a specific patient population …
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is launching a Women’s Health Programme to boost female participation in …
Nuvation Bio has reported updated long-term follow-up findings from the Phase II J201 trial assessing safusidenib in patients with chemotherapy- …
Rein Therapeutics has reported preliminary blinded 12-week findings from the Phase II RENEW clinical study of its lead drug, LTI-03, …
CG Oncology’s adenovirus-based oncolytic viral immunotherapy has shown significant improvements in a Phase III non-muscle invasive bladder cancer (NMIBC) trial. In …
Aclaris Therapeutics’ monoclonal antibody (mAb) failed to show benefit in a Phase II atopic dermatitis (AD) trial. The ADMIRATION trial (NCT07011706) …
Amylyx Pharmaceuticals has reported the data behind a Phase III trial win for its investigational glucagon-like peptide-1 (GLP-1) receptor antagonist …
Novo Nordisk has reported post hoc findings from the Phase III REDEFINE 1 trial evaluating its investigational combination therapy CagriSema …
The global medical technology market is expanding rapidly as ageing populations and rising healthcare needs drive demand. Asia is increasingly …